Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
Saved in:
| Title: | Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. |
|---|---|
| Authors: | Campone, M.1,2, Bondarenko, I.3, Brincat, S.4, Hotko, Y.5, Munster, P. N.6, Chmielowska, E.7, Fumoleau, P.8, Ward, R.9, Bardy-Bouxin, N.10, Leip, E.11, Turnbull, K.11, Zacharchuk, C.11, Epstein, R. J.12 |
| Source: | Annals of Oncology. Mar2012, Vol. 23 Issue 3, p610-617. 8p. 1 Diagram, 3 Charts, 4 Graphs. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
